Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 10,533 matching trials from the local directory fallback.

Filters: Active, not recruiting Clear all

Conditions: Obesity, Overweight
Interventions: Acetaminophen, NNC0662-0419, Oral contraceptive; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chronic Pain, Musculoskeletal Pain, Pain Disorders, Sleep Disturbance
Interventions: Weighted Blanket; Device
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Knee Injuries, Knee Sprain, Post-traumatic Osteoarthritis
Interventions: mCare PTOA Intervention; Behavioral
Lead sponsor: Keller Army Community Hospital; Federal
Eligibility: 18 Years to 54 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: West Point, New York

Conditions: Aortic Valve Replacement, Cardiac Rehabilitation, Coronary Heart Disease (CHD), Ethics, Heart Failure, Myocardial Infarction (MI), Percutaneous Coronary Intervention (PCI)
Interventions: More Support and Tools, Usual Care Group; Behavioral
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Mavacamten; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anxiety, Depression, Food Insecurity, Stress
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity
Interventions: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 47
States / cities: Costa Mesa, California • San Diego, California • Walnut Creek, California + 42 more

Conditions: Chikungunya Virus
Interventions: CHIKV VLP vaccine, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Interventions: Voro Urologic Scaffold; Device
Lead sponsor: Levee Medical, Inc.; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 15 more

Conditions: Obesity
Interventions: Comprehensive weight loss, Enhanced lifestyle changes, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®), Tirzepatide; Other · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Tumor
Interventions: IPN01195; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Grand Rapids, Michigan • Nashville, Tennessee • Dallas, Texas + 2 more

Conditions: Geographic Atrophy
Interventions: BI 1584862, Placebo-matching BI 1584862; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 43
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Abiraterone, BMS-986365, Docetaxel, Enzalutamide, Predinsone/Prednisolone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more

Conditions: Clinical Decision Support, Genetic Disease, Pediatrics, Predictive Model
Interventions: SIGHT Prompted Provider Message; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 1 Year to 20 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Interventions: Biospecimen Collection; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obesity, Overweight
Interventions: LY3537031, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Los Alamitos, California • Daytona Beach, Florida • Miami, Florida + 2 more

Conditions: Obesity, Overweight
Interventions: NNC0638-0355, Placebo (NNC0638-0355); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah

Conditions: Anxiety, Stress
Interventions: Audiobook, Box Breathing, Cyclic Sighing Breathing, Hypnosis; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Endometriosis
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Hypertrophic Cardiomyopathy (HCM)
Interventions: Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Patient- and provider-focused strategies, Patient-focused strategies, Provider-focused strategies; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Sylmar, California

Conditions: Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Pancreatic Ductal Adenocarcinoma, Solid Tumor
Interventions: IPN01194; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more

Conditions: Blood Pressure, Cardiovascular Diseases, Hypertension
Interventions: Blood Pressure Cuff, EKG, PPG; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ornithine Carbamoyltransferase Deficiency (Disorder), Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
Interventions: ECUR-506; Genetic
Lead sponsor: iECURE, Inc.; Industry
Eligibility: 24 Hours to 7 Months · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Search by objective public record fields.

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Weighted Blanket Use for Adults With Chronic Pain

Efficacy of an Evidence-based Telehealth Intervention in Modifying Health Behavior

The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Neonatal Neurodevelopmental Outcomes

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Pivotal Study of Voro Urologic Scaffold

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease

A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

Stress Management Program

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Multi-ethnic Multi-level Strategies and Behavioral Economics to Eliminate Hypertension Disparities in Los Angeles County

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Vital Signs Blood Pressure Trial

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency